Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Urinary Bladder Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Glioma 4Carcinoma, Transitional Cell 3Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1

Interventions

erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancers and FGFR Genetic Alterations × erdafitinib × 1 year × Clear all
NCT03825484 2025-06-13

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Janssen Scientific Affairs, LLC

Approved for marketing

Advanced Cancers and FGFR Genetic Alterations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡